MétaCan
Menu
Back to cohort
Record W2515214902 · doi:10.1053/j.ajkd.2016.06.014

Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis

2016· review· en· W2515214902 on OpenAlexafffund
P M Howse, Lyudmila Chibrikova, Laurie Twells, Brendan J. Barrett, John‐Michael Gamble

Bibliographic record

VenueAmerican Journal of Kidney Diseases · 2016
Typereview
Languageen
FieldMedicine
TopicDiabetes Treatment and Management
Canadian institutionsMemorial University of Newfoundland
FundersCanadian Institutes of Health ResearchNewfoundland and Labrador Centre for Applied Health Research
KeywordsMedicineIncretinInternal medicineSitagliptinPlaceboHypoglycemiaLinagliptinDiabetes mellitusVildagliptinType 2 diabetesContext (archaeology)Relative riskKidney diseaseRenal functionGlycated hemoglobinEndocrinologyConfidence intervalPathology

Abstract

fetched live from OpenAlex

Background The pharmacokinetics and pharmacodynamics of antidiabetic therapies for patients with type 2 diabetes are often altered in the context of chronic kidney disease (CKD). Study Design Systematic review and meta-analysis. Setting & Population Patients with type 2 diabetes and CKD. Selection Criteria for Studies 2 reviewers independently screened studies identified through bibliographic databases (Cochrane Library, PubMed, Embase, International Pharmaceutical Abstracts), clinical trial registries, and references from pertinent articles and clinical practice guidelines. Eligible studies included randomized controlled trials evaluating incretin-based therapy in adults with type 2 diabetes and estimated glomerular filtration rates < 60mL/min/1.73m 2 . Interventions Incretin-based therapies (dipeptidyl peptidase 4 inhibitors and glucagon-like peptide 1 receptor agonists) compared to placebo or active antidiabetic therapies. Outcomes Changes in glycated hemoglobin (HbA 1c ), hypoglycemia, mortality, change in fasting plasma glucose, cardiovascular events, and end-stage renal disease. Results Of 1,619 nonduplicate records screened, 13 studies were included. Compared to placebo, incretin-based therapies significantly reduced HbA 1c levels (n = 9; weighted mean difference, −0.64; 95% CI, −0.79 to −0.48; I 2 = 43%); however, compared with active comparators, they did not (n = 4; weighted mean difference, −0.07; 95% CI, −0.25 to 0.12; I 2 = 38%). Incretin-based therapies significantly increased the risk for hypoglycemia compared to placebo (n = 7; relative risk [RR], 1.38; 95% CI, 1.01-1.89; I 2 = 0%) but no effect was observed versus active comparators (n = 4; RR, 0.24; 95% CI, 0.03-1.94; I 2 = 52%). Limited evidence exists for all-cause mortality (placebo: n = 7 [RR, 1.21; 95% CI, 0.64-2.29; I 2 = 0%]; active comparators: n = 3 [RR, 0.70; 95% CI, 0.32-1.54; I 2 = 0%]). Limitations Variation among interventions, small number of studies, heterogeneity between studies, and high risk for attrition bias in 7 of the selected studies. Conclusions In patients with moderate or severe CKD, incretin-based therapies are effective in reducing HbA 1c levels. Hypoglycemic events are rare, and wide CIs for the association preclude any definitive conclusions. Likewise, wide CIs were observed for mortality, cardiovascular events, and end-stage renal disease.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.007
metaresearch head score (Gemma)0.018
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Meta-analysis · Consensus signal: Meta-analysis
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.016
Threshold uncertainty score0.037

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0070.018
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0160.030
Bibliometrics0.0030.004
Science and technology studies0.0000.001
Scholarly communication0.0020.002
Open science0.0020.001
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.013
GPT teacher head0.278
Teacher spread0.264 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designMeta-analysis
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations42
Published2016
Admission routes2
Has abstractno

Explore more

Same venueAmerican Journal of Kidney DiseasesSame topicDiabetes Treatment and ManagementFrench-language works237,207